What Is OCD and Why It Is Much More Than Just Perfectionism

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Obsessive compulsive disorder, or OCD, is a long lasting mental health disorder marked by recurrent obsessions, compulsions, or both. Obsessions are intrusive unwanted thoughts, urges, or mental images. Compulsions are repetitive behaviors or mental acts you feel driven to perform to reduce distress or to prevent a feared outcome. These symptoms can take more than an hour a day, cause significant distress and interfere with daily life.

People often use the term OCD to describe neatness, organization, or high standards. The medical definition is much more specific. A person with OCD can fear contamination, harm, moral failure, loss of control, or uncertainty itself. The response can include washing, checking, arranging, counting, praying, repeating phrases silently, seeking reassurance, or avoiding situations that trigger fear. Many adults know the rituals are excessive and still feel unable to stop.

The disorder is also common and impairing in real clinical terms. National data show that an estimated 1.2 percent of U.S. adults had OCD in the past year and about half of those adults had serious impairment. That helps explain why OCD affects work, school, relationships and routine tasks so strongly when symptoms take hold.

The biological difference between a habit and a compulsion

A habit is a repeated behavior that becomes familiar through practice. A compulsion is driven by distress and urgency. In OCD, the behavior or mental ritual is tied to an obsession and is performed to bring down anxiety or to prevent a feared event. The relief is usually brief. The fear then returns and the ritual starts again.

This is why OCD can feel hard to explain from the outside. If you check the stove once before leaving home, that can be ordinary caution. If you check it again and again because your mind keeps telling you a fire will start and you cannot get relief until the ritual feels complete, that fits the clinical pattern of compulsion. The same pattern can apply to washing, reviewing memories, rereading messages, checking your body for signs of illness, or silently repeating phrases in your head.

Compulsions also differ from ordinary habits because they often bring no pleasure. Clinical guidance notes that people with OCD generally do not get pleasure from compulsions, though they may get temporary relief from anxiety. That brief drop in distress can reinforce the cycle and make the urge return even stronger the next time an obsession appears.

Another point is that compulsions can be physical or mental. Some people wash, check, arrange or touch things in set patterns. Others count, pray, review, mentally cancel a thought, or ask for repeated reassurance. Hidden rituals can be missed for years because people around you may only see lateness, hesitation, avoidance, irritability, or repeated questions, not the internal ritual happening underneath.

How fear responses misfire in the brain

Current clinical sources state that the exact causes of OCD are still being studied, but biology plays a clear role. Brain imaging studies have shown differences in the frontal cortex and in subcortical brain areas involved in control of behavior and emotional responses. Researchers have also found that several brain areas, brain networks and biological processes are tied to obsessive thoughts, compulsive behavior and the fear and anxiety linked to them.

That brain level activity helps explain why OCD does not feel like a simple choice. The fear signal lands with too much force and stays active too long. A thought that another person could dismiss in a few seconds may feel urgent, dangerous and unfinished to you. The compulsion then acts like a fast relief valve. That relief teaches the brain to keep using the ritual, which can lock the disorder into a repeating cycle.

Genetics also appear to contribute. Clinical guidance notes that having a first degree relative with OCD is linked to a higher chance of developing the disorder. That does not point to one single gene or one simple cause. It does show that OCD sits partly in the biology of the brain rather than in personality labels such as neatness or perfectionism.

Symptoms often begin between late childhood and young adulthood. They can intensify during periods of stress and may shift in content over time. A person may move from contamination fears to checking rituals, from symmetry concerns to intrusive taboo thoughts, or from visible rituals to hidden mental acts. The core process stays the same. The brain keeps treating doubt and fear as threats that need an immediate ritual response.

The physical exhaustion of hiding daily rituals

OCD is mentally taxing, but it can also wear you down physically. Repeated handwashing can damage skin. Checking rituals can delay sleep and keep you stuck in the same room or doorway for long periods. Avoidance can shrink your daily routine and make basic tasks take far longer than they should. Clinical guidance also notes complications such as health issues from frequent washing, difficulty going to work or school, troubled relationships and a sharp drop in quality of life.

Hiding rituals adds another layer of strain. Many people with OCD feel shame or embarrassment and try to conceal symptoms. That can mean doing mental rituals silently during conversations, leaving early to complete checking routines in private, masking skin irritation from washing, or rerunning tasks after other people have gone to bed. The effort required to appear fine can leave you drained before the day is even half over.

This hidden burden is one reason OCD is often diagnosed late. Symptoms can overlap with anxiety, low mood, perfectionistic behavior, indecision, or simple overthinking. People may also avoid telling a clinician about taboo intrusive thoughts out of fear of judgment. A careful evaluation looks at the full pattern, including time spent on rituals, the urge to repeat them, the degree of distress and the level of interference in daily life.

Conclusion

As research continues to map how obsessive loops are tied to brain function, we at Rose Hill Life Sciences view OCD through the lens of neurological recovery and therapeutic integration. We are a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and are based in Massachusetts.



Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.